Clinical Trial Update: REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide (REVLIMID) for radioiodine-unresponsive papillary and follicular thyroid carcinomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Neoplasms

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Kenneth Ain | Conditions: Thyroid Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-06-12